Want to see TARA full AI Analyst Report?
TARA Stock Chart & Stats
$4.02
$0.02(0.50%)
At close: 4:00 PM EDT
$4.02
$0.02(0.50%)
Day’s Range― - ―
52-Week Range$3.02 - $7.82
Previous Close$4.11
Volume533.55K
Average Volume (3M)638.24K
Market Cap
$228.70M
Enterprise Value$93.30
Total Cash (Recent Filing)$17.08M
Total Debt (Recent Filing)$2.75M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Oct 29, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding59,095,490
10 Day Avg. Volume379,912
30 Day Avg. Volume638,236
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-4.04
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.00Price Target Upside497.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage limits debt-servicing pressure and preserves financial flexibility while Protara funds clinical development. This reduces solvency risk relative to more debt-dependent biotechs, although it does not eliminate the need for future capital.
Late-Stage Pipeline ProgressProgress toward completing ADVANCED-2 represents a meaningful development milestone for TARA-002 in BCG-unresponsive NMIBC. Advancing a late-stage asset can improve the company’s strategic position and potential commercialization prospects if clinical outcomes support approval.
Broader Clinical Development PlanThe redesigned ADVANCED-3 protocol is intended to evaluate TARA-002 in a broader high-grade, high-risk NMIBC population and expand data available near a potential launch. This may improve evidence breadth and future development optionality.
Bears Say
No Product RevenueThe absence of product revenue confirms that Protara remains dependent on clinical execution and eventual regulatory success rather than an established commercial franchise. This leaves future cash generation uncertain and increases exposure to development delays or failed trials.
Widening Losses And Cash BurnPersistent negative cash generation and widening losses indicate that operating expenses remain substantial without offsetting revenue. Continued development will likely require external funding, creating financing dependence and limiting strategic flexibility if capital markets become less accessible.
Potential Equity DilutionDoubling authorized shares improves Protara’s ability to fund operations and clinical programs, but it also creates substantial capacity for future equity issuance. Repeated financing could dilute existing holders and reduce their share of any eventual product value.
Protara Therapeutics News
TARA FAQ
What was Protara Therapeutics, Inc.’s price range in the past 12 months?
Protara Therapeutics, Inc. lowest stock price was $3.02 and its highest was $7.82 in the past 12 months.
What is Protara Therapeutics, Inc.’s market cap?
Protara Therapeutics, Inc.’s market cap is $228.70M.
When is Protara Therapeutics, Inc.’s upcoming earnings report date?
Protara Therapeutics, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 64 days.
How were Protara Therapeutics, Inc.’s earnings last quarter?
Protara Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.326 by -$0.034.
Is Protara Therapeutics, Inc. overvalued?
According to Wall Street analysts Protara Therapeutics, Inc.’s price is currently Undervalued.
Does Protara Therapeutics, Inc. pay dividends?
Protara Therapeutics, Inc. does not currently pay dividends.
What is Protara Therapeutics, Inc.’s EPS estimate?
Protara Therapeutics, Inc.’s EPS estimate is -0.37.
How many shares outstanding does Protara Therapeutics, Inc. have?
Protara Therapeutics, Inc. has 59,095,490 shares outstanding.
What happened to Protara Therapeutics, Inc.’s price movement after its last earnings report?
Protara Therapeutics, Inc. reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.326. Following the earnings report the stock price went down -4.866%.
Which hedge fund is a major shareholder of Protara Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protara Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (497.01% Upside)
$24.00 (497.01% Upside)
Blogger Sentiment
Bullish
TARA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 118.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $882.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.21%
Trailing 12-Months
Company Description
Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
TARA Stock 12 Month Forecast
Average Price Target
$24.00
▲(497.01% Upside)
Technical Analysis
Minerva Neurosciences
―
Anavex Life Sciences
―
AC Immune SA
―
ProMIS Neurosciences
―
NRX Pharmaceuticals
―
Ownership Overview
2.84% Insiders
6.69% Mutual Funds
29.84% Other Institutional Investors
51.51% Public Companies and
Individual Investors